First oral hypoglycaemic licensed for add-on therapy in type I diabetes

The SGLT2 inhibitor dapagliflozin (Forxiga) can now...

New MIMS table helps GPs adjust antidiabetic doses in renal impairment

Prescribers can now consult a handy MIMS table to check...

Fingerprick-free glucose monitoring system available on the NHS

A glucose monitoring system that does not require regular...

New combination tablet for type II diabetes

Qtern contains a fixed-dose combination of saxagliptin...

Renal impairment warnings relaxed for metformin products

Metformin-containing products can now be used in patients...

NICE revises its decision on dapagliflozin in triple therapy

SGLT2 inhibitors endorsed for NHS use as monotherapies

Canagliflozin, dapagliflozin and empagliflozin have...

Pictorial guide to diabetes devices now available on MIMS website

GPs and MIMS subscribers can now view images and key...

Foot care reminder for canagliflozin prescribing

Healthcare professionals have been reminded of the...

New advice on diabetic ketoacidosis risk with SGLT2 inhibitors

Measures to reduce the risk of rare diabetic ketoacidosis...

MIMS publishes summary of new NICE diabetes guidance

A quick-reference MIMS summary of the recently revised...

Albiglutide: new once-weekly GLP-1 receptor agonist for diabetes

Eperzan (albiglutide) is indicated for the treatment...

GPs warned of potential insulin shortages

Sanofi has announced a possible supply shortage of...

New for diabetes: empagliflozin/metformin fixed-dose combination

The SGLT2 inhibitor empagliflozin (Jardiance) is now...

First biosimilar insulin launches

Abasaglar is a new biosimilar version of the long-acting...

New high-strength insulin glargine formulation

Toujeo (insulin glargine) is a 300 units/ml formulation...

Novopen 4 insulin device discontinued

SGLT2 inhibitors: risk of diabetic ketoacidosis

Patients receiving SGLT2 inhibitors (canagliflozin,...

Humapen Memoir insulin pen discontinued

Higher strength Humalog insulin pen now available